CEL-SCI Corp - Company Profile

Powered by

All the sales intelligence you need on CEL-SCI Corp in one solution.

$195 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how CEL-SCI Corp fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with CEL-SCI Corp.

Back to companies

CEL-SCI Corp: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

CEL-SCI Corp (CEL-SCI) is a biotechnology company focused on new immunotherapy products for treating cancer, autoimmune, and infectious diseases. Its core capabilities include drug discovery, research, development, and manufacture of compound biological substances. The company's lead candidate, Multikine (leukocyte interleukin), is an underdeveloped biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules to treat certain head and neck cancers. It is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine using its Ligand Epitope Antigen Presentation System (LEAPS) to potentially treat rheumatoid arthritis, bacterial, viral, and parasitic infections, autoimmune conditions, allergies, transplantation rejection, and cancer. CEL-SCI is headquartered in Vienna, Virginia, the US.

 Gain a 360-degree view of CEL-SCI Corp and make more informed decisions for your business Gain a 360-degree view of CEL-SCI Corp and make more informed decisions for your business Learn more
Headquarters United States of America
Address Suite 802, 8229 Boone Blvd ., Vienna, Virginia, 22182
Website www.cel-sci.com
Telephone 1 703 5069460
No of Employees 43
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CVM (AFM)
EPS XYZ
Net Income (2024) XYZ 5.6% (2024 vs 2023)
Market Cap* $11.9M
Net Profit Margin (0 vs) XYZ 0.0% (2024 vs 2023)
   
* As of and is in US$
View CEL-SCI Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

CEL-SCI Corp premium industry data and analytics

15+

Clinical Trials

Determine CEL-SCI Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

7

Pipeline Drugs

Identify which of CEL-SCI Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for CEL-SCI Corp’s relevant decision makers and contact details.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Catalyst Calendar

Proactively evaluate CEL-SCI Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Brands
Pipeline Multikine
Multikine:
HPV
XYZ
XYZ
XYZ
Understand CEL-SCI Corp portfolio and identify potential areas for collaboration Understand CEL-SCI Corp portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Plans/Strategy In February, the company announced its plans to initiate Multikine confirmatory phase 3 cancer trial.
2024 Contracts/Agreements In October, the company renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirmatory registration study of Multikine.
2024 Regulatory Approval In September, the company received regulatory approval from the United Kingdom’s Healthcare Products Regulatory Agency (MHRA) granting Multikine.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters CEL-SCI Corp Bioqual Inc AVAX Technologies Inc Adicet Bio Inc Compass Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Vienna Rockville Philadelphia Boston Boston
State/Province Virginia Maryland Pennsylvania Massachusetts Massachusetts
No. of Employees 43 108 29 102 39
Entity Type Public Public Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Geert R. Kersten Chief Executive Officer; Director Executive Board 1995 66
Eyal Talor, PhD Chief Scientific Officer Senior Management 2009 68
Patricia B. Prichep Chief Financial and Operations Officer Senior Management 2024 73
Robert Watson Chairman Non Executive Board 2024 67
William Jones Quality Assurance Advisor Senior Management 2025 -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into CEL-SCI Corp key executives to enhance your sales strategy Gain insight into CEL-SCI Corp key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?